Observational studyAsian Pacific journal of cancer prevention : APJCP2025
Molybdenum Deficiency among Esophageal Cancer Patients.
Observational study in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests that deficiencies in trace elements, particularly molybdenum, may contribute to Esophageal Cancer (EC) pathogenesis. Molybdenum is an essential micronutrient that plays a key role in detoxifying carcinogenic compounds through its involvement in enzymatic pathways, including xanthine oxidase activity. This study aims to evaluate serum molybdenum levels in patients with histologically confirmed EC and compare them to healthy controls to assess the association between molybdenum deficiency and EC incidence. MATERIALS AND
methodsThis prospective, single-center observational study was conducted at a regional cancer center in Srinagar, Kashmir, India from June 2021 to June 2023. Patients with histologically confirmed EC were included as the study group, while age- and gender-matched healthy volunteers served as controls. Serum molybdenum levels were measured using atomic absorption spectrophotometry.
resultsA total of 400 participants were enrolled. The study group had a mean age of 62.1 ± 12.61 years, with 58.5% males. The mean serum molybdenum level in esophageal cancer patients was significantly lower than that of the control group (0.79 ± 0.452 vs 2.33 ± 0.707, p < 0.001). The gender-based comparison showed that males in the study group had a significantly lower mean serum molybdenum level than male controls (p <0.001), with a similar trend observed in females.
conclusionMolybdenum deficiency may be associated with an increased risk of EC by impairing carcinogen detoxification. Further research is needed to explore its preventive and therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.